NCT05754684RecruitingPhase 2
Quadruple Immunotherapy for Neuroblastoma
Quadruple Immunotherapy for Paediatric Patients With Relapsed or Refractory Neuroblastoma
Source: ClinicalTrials.gov · Last updated 15 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- First submitted
- 18 Nov 2022
- Start date
- 1 Jan 2022
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Hong Kong Children's Hospital
- Diseases
- Neuroblastoma
- NCT number
- NCT05754684
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 29
- From 1 Jan 2022 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- HIV infection
- Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy \<1 month
Other
- Pregnant or lactating woman
- Patients for whom conventional treatment is deemed more appropriate
Who the study is looking for
- relapsed or refractory neuroblastoma
- Adequate organ function: creatinine clearance ≥40 ml/min/1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU/L, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air
- Karnofsky or Lansky performance status score ≥50
- Has an appropriate HLA-haploidentical NK-cell donor available
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hong Kong Children's Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.